Chiesi Farmaceutici SpA, a family-controlled pharmaceutical company based in Parma, Italy, has teamed up with Aptuit LLC, a US contract research organisation, to discover new compounds for idiopathic pulmonary fibrosis (IPF), a serious, chronic lung disease.